SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

SU Group Holdings Ltd. engages in the provision of security-related engineering services, and security guarding and screening services. It operates through the Security-Related Engineering Services and Security Guarding and Screening Services segments. The company was founded by Ming Chan in 1998 and is headquartered in Hong Kong.

SU Group Holdings Ltd. - Ordinary Shares - Class A

SU Group Holdings Ltd

SU Group Holdings Ltd (SUGP) is a top trending stock, with widespread community discussion focused on its ultra-low share float, high short interest, and presence on the Reg SHO list, fueling fervent speculation for a significant short squeeze. Traders are keenly drawing comparisons to past volatile movers in the security sector. The community is actively anticipating upcoming earnings and potential contract announcements as key catalysts for a breakout.

Alibaba Group Holding Ltd. engages in providing technology infrastructure and marketing reach. It operates through the following business segments: China Commerce, International Commerce, Local Consumer Services, Cainiao, Cloud, Digital Media and Entertainment, and Innovation Initiatives and Others segments. The Core Commerce segment consists of platforms operating in retail and wholesale. The China Commerce segment includes China commerce retail and wholesale businesses. The International Commerce segment focuses on international commerce retail and wholesale businesses. The Local Consumer Services segment is involved in To-Home businesses, which include Ele.me, local services and delivery platform, and Taoxianda, and To-Destination segment businesses which include Amap, the provider of mobile digital map, navigation and real-time traffic information, and restaurant and local services guide platform. The Cainiao segment has Cainiao Network and offers domestic and international one-stop-shop logistics services and supply chain management solution. The Cloud segment includes Alibaba Cloud and DingTalk. The company was founded by Chung Tsai and Yun Ma on June 28, 1999 and is headquartered in Hangzhou, China.

Alibaba Group Holding Ltd - ADR

Alibaba Group Holding Ltd

Alibaba is generating significant buzz as investors anticipate a major re-rating for Chinese tech, driven by the company's accelerating AI and cloud growth and strategic investments in startups like MiniMax. The community is actively discussing a potential technical breakout and short squeeze, fueled by the belief that the stock is deeply undervalued and poised for substantial upside as the narrative shifts towards China's AI dominance.

Alphabet, Inc. is a holding company, which engages in software, health care, transportation, and other technologies. It operates through the following segments: Google Services, Google Cloud, and Other Bets. The Google Services segment includes products and services, such as ads, Android, Chrome, devices, Google Maps, Google Play, Search, and YouTube. The Google Cloud segment refers to infrastructure and platform services, collaboration tools, and other services for enterprise customers. The Other Bets segment relates to the sale of healthcare-related services and internet services. The company was founded by Lawrence E. Page and Sergey Mikhaylovich Brin on October 2, 2015 and is headquartered in Mountain View, CA.

Alphabet Inc - Ordinary Shares - Class A

Alphabet Inc Class A

Alphabet is trending due to a significant partnership with Apple, leveraging its Gemini AI to power Siri, alongside new AI-driven shopping integrations with major retailers like Walmart. This development is widely seen as a major validation for Google's AI technology, fueling community discussion about its leadership in the AI race and its growing market capitalization. Investors are actively debating the stock's long-term strategic positioning, especially as its AI ecosystem expands through various collaborations.

Pagaya Technologies Ltd. engages in the development of AI and data networks for the financial industry. Its product deploys data science, machine learning and AI technology to evaluate the customers' applications in real time. The company was founded by Gal Krubiner, Sanjiv Das, Yahav Yulzari, and Avital Pardo on March 20, 2016 and is headquartered in New York, NY.

Pagaya Technologies Ltd - Ordinary Shares - Class A

Pagaya Technologies Ltd

Pagaya Technologies is trending amidst political discussions regarding potential credit card interest rate caps, prompting community debate about its business model, which predominantly focuses on personal and auto loans. Despite recent positive business developments like successful securitization deals and upcoming earnings, the stock is navigating broader fintech sector volatility and concerns over perceived market manipulation. Many investors remain optimistic, emphasizing the company's AI-driven lending platform and strong fundamentals as key drivers for future growth amidst anticipated macroeconomic shifts like potential interest rate reductions.

United States Antimony Corp. engages in the extraction, processing and sale of antimony, zeolite, silver, and gold products. It operates through the following segments: United States Antimony Operations, Mexican Antimony Operations, Precious Metals Recovery, and United States Zeolite Operations. The company was founded by John C. Lawrence in June 1968 and is headquartered in Thompson Falls, MT.

United States Antimony Corp.

United States Antimony Corp

United States Antimony (UAMY) is trending as investors increasingly recognize its critical role as the sole vertically integrated antimony producer in North America. Community discussion is highly bullish, driven by escalating geopolitical tensions highlighting the immediate need for domestic supply in defense and green energy sectors. Expectations are high for significant government investment and contract announcements to bolster UAMY's production and reduce reliance on foreign sources.

Apple, Inc. engages in the design, manufacture, and sale of smartphones, personal computers, tablets, wearables and accessories, and other varieties of related services. It operates through the following geographical segments: Americas, Europe, Greater China, Japan, and Rest of Asia Pacific. The Americas segment includes North and South America. The Europe segment consists of European countries, as well as India, the Middle East, and Africa. The Greater China segment comprises China, Hong Kong, and Taiwan. The Rest of Asia Pacific segment includes Australia and Asian countries. Its products and services include iPhone, Mac, iPad, AirPods, Apple TV, Apple Watch, Beats products, AppleCare, iCloud, digital content stores, streaming, and licensing services. The company was founded by Steven Paul Jobs, Ronald Gerald Wayne, and Stephen G. Wozniak in April 1976 and is headquartered in Cupertino, CA.

Apple Inc

Apple is trending as reports of a potential partnership with Google's Gemini AI for Siri fuel community debate over its innovation strategy and future growth. This comes amidst discussions of potential CEO succession and the stock's recent multi-day pullback, prompting investors to weigh oversold conditions against a clear AI catalyst.

Biodesix, Inc. provides blood-based diagnostics services for patients with lung disease. The firm offers GeneStrat, a genomic blood test for patients who have been diagnosed with advanced lung cancer and VeriStrat, a serum proteomic test that provides prognostic and predictive information for patients with non-small cell lung cancer. It also offers six diagnostic tests including: Nodify XL2, Nodify CDT, GeneStrat, VeriStrat, Bio-Rad SARS-CoV-2 ddPCR test and the Platelia SARS-CoV-2 test. The company was founded by David Brunel and Robert E. Cawthorn in 2005 and is headquartered in Louisville, CO.

Biodesix Inc

Biodesix is trending following robust preliminary Q4 and full-year 2025 results that exceeded guidance, reconfirming expectations for positive Adjusted EBITDA. This strong financial update, coupled with a significant insider purchase and an expanded partnership with Bio-Rad, is driving community excitement around potential short squeezes and takeover speculation in the precision lung diagnostics space.

JD.com, Inc. is a technology-driven E-commerce company, which engages in the sale of electronics products and general merchandise products, including audio, video products, and books. It operates in the following segments: JD Retail, JD Logistics, and New Businesses. The JD Retail segment offers online retail, online marketplace, and marketing services. The JD Logistics segment includes internal and external logistics businesses. The New Businesses segment is composed of JD Property, Jingxi, overseas businesses and technology initiatives. The company was founded on June 18, 1998, by Qiang Dong Liu and is headquartered in Beijing, China.

JD.com Inc - ADR

JD.com is trending amidst community discussions highlighting recent substantial share repurchases, with a considerable amount executed in Q4, signaling management's commitment to shareholder value. Despite its perceived undervaluation and past underperformance, many anticipate a significant re-rating, fueled by the company's accelerating AI commercialization and a broader optimistic outlook for the Chinese tech sector. This blend of internal strategic initiatives and external market sentiment positions JD as a key discussion point among value-focused investors.

Nuvation Bio, Inc. is a biopharmaceutical company tackling some of the unmet needs in oncology by developing differentiated and novel therapeutic candidates. Its proprietary portfolio includes six novel and mechanistically distinct oncology therapeutic product candidates, each targeting some of the most difficult-to-treat types of cancer. The company was founded by David Hung on March 20, 2018 and is headquartered in New York, NY.

Nuvation Bio Inc - Ordinary Shares - Class A

Nuvation Bio is gaining significant attention following robust launch performance for its lead oncology drug IBTROZI, which boasts an impressive 50-month median duration of response. Investors are also energized by positive clinical data for pipeline asset safusidenib and the anticipation of a major EU partnership, with many in the community trusting CEO Dr. David Hung's track record for long-term value creation and potential future M&A.

Critical Metals Corp. engages in the mining, exploration, and development of lithium metals. It owns Wolfsberg Project and Tanbreez Project. The company was founded on October 24, 2022 and is headquartered in British Virgin Islands.

Critical Metals Corp.

Critical Metals Corp. ($CRML) is experiencing significant market attention amidst renewed geopolitical interest in Greenland's vast rare earth deposits, driven by discussions surrounding U.S. national security and securing critical mineral supply chains. The community is actively discussing upcoming high-level meetings between U.S., Danish, and Greenlandic officials, with many speculating on potential U.S. access to these strategic resources, including CRML's Tanbreez project. Despite recent price volatility attributed to perceived "short attacks" or manipulation, investors are buying dips, expressing strong conviction in a substantial upside as global demand for critical metals intensifies.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

<ul class="summary-bullets"><li>The outlook for Q4 and FY2025 exceeds the analyst consensus estimate of $24.95 million and $84.65 million, respectively, according to Fiscal AI data.&nbsp;</li><li>Biodesix said revenue gains were largely fueled by the company’s lung diagnostics segment.</li><li>Test volumes climbed to 18,000 in Q4 and 62,600 for the year.</li></ul>Biodesix Inc. (BDSX) stock surged over 23% in Monday’s premarket after the Colorado-based diagnostics firm provided a strong outlook for the fourth quarter (Q4) and fiscal year 2025.&nbsp;The company expects Q4 revenue of $28.8 million, a 41% year-over-year (YoY) increase, while full-year revenue is estimated at $88.5 million, up 24% YoY. The outlook for Q4 and FY2025 exceeds the analyst consensus estimate of $24.95 million and $84.65 million, respectively, according to Fiscal AI data.&nbsp;<h2 class="st-heading-2">Growth Driven By Lung Diagnostics</h2>Biodesix said revenue gains were largely fueled by the company’s lung diagnostics segment, which is estimated to have generated $25.2 million in Q4 and $79.2 million for the full year. The results reflect a 47% and 22% YoY increase, respectively.&nbsp;Test volumes climbed to 18,000 in Q4 and 62,600 for the year, rising 23% and 15% from the previous year. The increase was driven by higher test volumes, stronger revenue per test, and about $1 million in collections from older claims.&nbsp;<blockquote>“Biodesix finished 2025 with a strong fourth quarter, delivering full year estimated revenue of $88.5 million, exceeding the top end of our increased guidance of $84-$86 million.”-Scott Hutton, CEO, Biodesix</blockquote>On Stocktwits, retail sentiment around&nbsp;<a href="https://stocktwits.com/symbol/BDSX">Biodesix stock</a> jumped to ‘extremely bullish’ from ‘bearish’ territory the previous day. Message volume shifted to ‘extremely high’ from ‘high’ levels in 24 hours.&nbsp;<figure class="image"><img src="https://news.stocktwits-cdn.com/Screenshot_2026_01_12_084117_png_27b632f1b5.webp" alt="BDSX’s Sentiment Meter and Message Volume as of 08:30 a.m. ET on Jan. 12, 2026 | Source: Stocktwits" width="931" height="98"><figcaption>BDSX’s Sentiment Meter and Message Volume as of 08:30 a.m. ET on Jan. 12, 2026 | Source: Stocktwits</figcaption></figure><h2 class="st-heading-2">Development Services&nbsp;</h2>The company’s development services segment contributed an estimated $3.6 million in Q4 and $9.3 million for 2025, representing growth of 13% and 41% over the prior year, respectively.&nbsp;“Based on our strong revenue flow-through and operating leverage, we are affirming our expectation of positive Adjusted EBITDA in the fourth quarter,” added Hutton.&nbsp;Biodesix said it ended 2025 with $19.0 million in cash and cash equivalents, a 14% increase over the previous quarter.&nbsp;BDSX stock declined by over 77% in the last 12 months.&nbsp;Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/apple-captures-20-of-global-smartphone-market/cmU96DMR4E4">Apple Captures 20% Of Global Smartphone Market, But Rising Memory Costs Cast Shadow On 2026 Growth</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Biodesix logo is seen displayed on a smartphone screen.

BDSX Stock Shot Up 23% Pre-Market Today — What’s Fueling The Surge? 

The company expects Q4 revenue of $28.8 million, a 41% year-over-year increase, while full-year revenue is estimated at $88.5 million, up 24% year-over-year.

This Diagnostics Stock Is Surging 23% Pre-Market Today – Here’s Why 

Equity

SOLV Acquires Acera Surgical to Expand Advanced Wound Care Portfolio

Solventum buys Acera Surgical for $725M upfront to enter tissue matrices, expanding MedSurg and wound care.

Biodesix, Inc. (NASDAQ:BDSX) Receives Average Rating of "Moderate Buy" from Brokerages

Shares of Biodesix, Inc. (NASDAQ:BDSX - Get Free Report) have received a consensus rating of "Moderate Buy" from the six brokerages that are covering the stock, MarketBeat.com reports. One analyst...

Cencora to Acquire OneOncology to Expand Community Oncology Solutions

COR's $3.6 billion move to take control of OneOncology boosts its pharma-centric strategy and lifts its long-term growth outlook despite a short-term dip.

Wall Street Analysts Believe Biodesix (BDSX) Could Rally 325.67%: Here's is How to Trade

The mean of analysts' price targets for Biodesix (BDSX) points to a 325.7% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Biodesix, Inc. (NASDAQ:BDSX) Given Average Recommendation of "Moderate Buy" by Analysts

Shares of Biodesix, Inc. (NASDAQ:BDSX - Get Free Report) have earned an average recommendation of "Moderate Buy" from the six ratings firms that are currently covering the stock, Marketbeat.com...

Biodesix, Inc. (BDSX) Reports Q3 Loss, Tops Revenue Estimates

Biodesix (BDSX) delivered earnings and revenue surprises of +27.50% and +2.68%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?

Teladoc (TDOC) Reports Q3 Loss, Beats Revenue Estimates

Teladoc (TDOC) delivered earnings and revenue surprises of +19.23% and +0.23%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?

Revvity (RVTY) Surpasses Q3 Earnings Estimates

Revvity (RVTY) delivered earnings and revenue surprises of +3.51% and -0.15%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?

Biodesix, Inc. (BDSX) Reports Q2 Loss, Tops Revenue Estimates

Biodesix (BDSX) delivered earnings and revenue surprises of -14.29% and +7.34%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Short-Term Volatility, Then Markets Move On

Sustained Risk-Off Until Fed Path Is Clear

Little Impact — Fundamentals Still Rule

Other – Comment Below

Markets pulled back after reports that the DOJ opened a criminal investigation into Federal Reserve Chair Jerome Powell, raising concerns about central bank independence. With rate cuts, inflation, and political pressure all in focus, how do you think this standoff will impact markets in 2026?

How Will the Powell Investigation Impact Markets in 2026?

Stocktwits

Stocktwits Polls

The company significantly beat Q4 and FY25 revenue guidance, with Q4 sales up 41% year-over-year, igniting investor excitement.

With a tiny free float and analyst targets up to $40, many are speculating on a major short squeeze opportunity.

Traders are actively watching this stock as it rockets over 40% higher on heavy volume, hitting various profit targets and breaking key resistance levels.

Despite strong revenue, some traders are noting concerns about the company's low cash reserves and potential for future dilution.

BDSX
Biodesix Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest BDSX News

BDSXBiodesix Inc